A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of a Multiple Oral Dose of VV261 Tablets in Chinese Healthy Participants.
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled, multiple ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV261 tablets in healthy adults.
详细描述
This study is a randomized, double-blind, placebo-controlled trial designed to enroll a total of 16 participants. It initially comprises two dose groups administered sequentially from the low-dose group to the high-dose group, with eight participants in each group randomly assigned to either the investigational drug or placebo. The dose escalation levels were set at 600 mg and 900 mg, administered three times daily (with an 8-hour interval) for 7.5 consecutive days, followed by a final dose on the morning of day 8, totaling 22 doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 18 to 45 years old, males or females;
- •Males weight no less than 50 kg, females weight no less than 45 kg, with body mass index of 19 to 26 kg/m^2;
- •Vital signs examination, physical examination, laboratory examination ,electrocardiogram examination chest CT and B-ultrasound of liver, gallbladder, pancreas, spleen, kidney and thyroid results are normal or considered abnormal without clinical significance by the investigator;
- •Participants who are willing to take proper contraceptive methods during the study and within 3 months after the the last administration;
- •Participants who are able to understand and follow the study protocol and instructions; participants who have voluntarily decided to participate in this study, and sign the informed consent form.
排除标准
- •Participants with hypersensitivity to preparation or any of the excipients;
- •Participants with allergic constitution (such as asthma, urticaria, eczematous dermatitis and other allergic diseases), or have a history of drug or food allergy;
- •Participants with central nervous system, cardiovascular system, gastrointestinal, respiratory system, urinary, hematologic, or metabolic disorders that require medical intervention or other diseases (such as psychiatric history) that are not suitable for clinical trials;participants with a history of gastrointestinal conditions that may impair drug absorption (e.g., gastrectomy or small intestine resection, atrophic gastritis, gastrointestinal ulcers or perforations/fistulas, gastrointestinal bleeding, or obstruction);participants with previous surgery that may significantly affect the body's metabolic process or safety evaluation of the study drug (such as liver, gallbladder, kidney, splenectomy, gastrointestinal resection or excessive blood loss that affects drug absorption, distribution, metabolism)
- •Participants with a history of diseases affecting bone marrow hematopoietic function or reducing immunological function (including leukemia, myelodysplastic syndrome, aplastic anemia, systemic lupus erythematosus, rheumatoid arthritis, etc.) or treatment history (tumor chemotherapy or radiotherapy, use of immunosuppressants, etc.);
- •Participants with a history of spleen diseases;
- •If any of the following parameters were considered abnormal with clinical significance: white blood cell count, red blood cell count, platelet count, reticulocyte count, and absolute neutrophil count;
- •If any of the following parameters were considered abnormal with clinical significance: total bilirubin, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase;
- •Participants who have received blood transfusion or used blood products within 3 months before screening or who have lost more than ≥400 mL of blood due to other reasons (excluding menstruation);
- •Participants who have participated in clinical trials and received drugs within 3 months before screening;
- •Participants who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 2 weeks before screening;
- •Participants who have received vaccination within the first 2 weeks before screening, or planned to receive any vaccine during the trial or within 1 week after the end of the study;
- •Participants with a history of drug abuse within 1 year before screening or positive urine drug screening within 1 year before screening results (morphine, tetrahydrocannabinol, methamphetamine, dimethylene diphenazine , ketamine, and cocaine);
- •Participants who drink more than 14 standard units or at least twice a day per week within one year before screening,(one standard unit equals 200 mL of beer with 5% alcohol or 25 mL of white wine with 40% alcohol content or 85 mL of red wine with 12% alcohol) or participants with breath alcohol test >0 mg/100 mL;
- •Participants who smok more than 5 cigarettes a day within one year before screening;
- •Participants who can't quit smoking or drinking during the trial period;
- •Participants who are positive for hepatitis B virus surface antigen, hepatitis C virus antibody, treponema pallidum antibody or human immunodeficiency virus antibody (Anti-HIV);
- •Participants who cannot tolerate blood collection with intravenous indwelling needles or blood fainting;
- •Participants with lactose intolerance or cannot comply with a uniform diet (such as special dietary requirements, intolerance of standard meals, etc.), Participants who have consumed excessive amounts of strong tea, coffee or caffeinated beverages in the 3 months before screening;
- •Participants with difficulty in swallowing tablets;
- •Pregnant or lactating women; participants whose spouses or partners intend to become pregnant, plan sperm or oocyte donation within 3 months after the last dose, or decline to use acceptable effective contraception；
- •The investigator believes that there are other unsuitable factors to participate this trial.
结局指标
主要结局
Cmax
时间窗: Baseline to 72 hours after the last administration
Maximum observed plasma concentration
Tmax
时间窗: Baseline to 72 hours after the last administration
Time at which Cmax occurs
Ctrough
时间窗: Baseline to 72 hours after the last administration
Minimum observed steady-state plasma concentration
AUC0-t
时间窗: Baseline to 72 hours after the last administration
Area under the plasma concentration time curve from time zero to the last measurable concentration
AUC0-∞
时间窗: Baseline to 72 hours after the last administration
Area under the plasma concentration-time curve from time zero to infinity
t1/2
时间窗: Baseline to 72 hours after the last administration
Half life of elimination
CL/F
时间窗: Baseline to 72 hours after the last administration
Apparent clearance
mean Resident Time
时间窗: Baseline to 72 hours after the last administration
Mean Resident Time from time zero to infinity/the last
Vd/F
时间窗: Baseline to 72 hours after the last administration
Apparent volume of distribution during the terminal phase
Incidence of Treatment-Emergent Adverse Events
时间窗: Baseline to 7days after the last administration
Incidence of Treatment-Emergent Adverse Events
次要结局
未报告次要终点